SCHEMBL3588839

SCHEMBL3588839

CCS(=O)(=O)Nc1ccc(-c2ccc(C(N)=O)c3n[c]nn23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 3/20 0.44
HPGD P15428 6/20 0.39
TP53 P04637 3/20 0.36
RXFP1 Q9HBX9 2/20 0.36
LMNA P02545 2/20 0.36
KIF11 P52732 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GLA P06280 2/20 0.36
GAA P10253 2/20 0.36
PKM P14618 2/20 0.36
MAPT P10636 2/20 0.36
PLK4 O00444 1/20 0.35
DAPK3 O43293 1/20 0.35
DYRK3 O43781 1/20 0.35
JAK2 O60674 1/20 0.35
ROCK2 O75116 1/20 0.35
MAP4K4 O95819 1/20 0.35
CDK1 P06493 1/20 0.35
RPS6KB1 P23443 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594492 0.84 NTRK1 (0.34) KDM4EALDH1A1GLAGAACLK4
SCHEMBL3583976 0.80 SYK (0.34) PLK4DAPK3MAP4K4MAP4K2ROCK1
SCHEMBL3593157 0.80 TAAR1 (0.38) PGRTP53JAK2CLK4MEN1
SCHEMBL3595165 0.79 IKBKB (0.34) HPGDKDM4EALDH1A1GSK3APRKCD
SCHEMBL3601959 0.79 MAP2K1 (0.36) KDM4EMAPTCLK4HSD17B10MEN1
SCHEMBL3200519 0.79 MAP2K1 (0.36) KDM4EDYRK1ACLK4MKNK2CHUK
SCHEMBL2730005 0.78 PARP1 (0.38) DYRK1ACLK4TSHRIKBKBCHUK
SCHEMBL2363030 0.78 NTRK1 (0.43) HPGDRXFP1LMNAKDM4EALDH1A1
SCHEMBL3082604 0.77 MAP2K1 (0.49) HPGDKDM4EALDH1A1CLK4HSD17B10
SCHEMBL3090230 0.77 NTRK1 (0.47) LMNAKDM4EALDH1A1GAAMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9771362-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-09-26 US disclosed
US-20170066762-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-03-09 US disclosed
US-9394301-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-07-19 US disclosed
US-20150246915-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-09-03 US disclosed
US-9012633-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-04-21 US disclosed
US-20140155594-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-06-05 US disclosed
US-8431596-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-04-30 US disclosed
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-11-25 US disclosed
EP-2217578-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2010-08-18 EP disclosed
WO-2009047514-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246915-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 PGR 1024/4885HPGD 3521/4885TP53 291/4885
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 PGR 1024/4885HPGD 3521/4885TP53 291/4885
US-20140155594-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 PGR 1024/4885HPGD 3521/4885TP53 291/4885
US-20170066762-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 PGR 1024/4885HPGD 3521/4885TP53 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.